ClinicalTrials.gg
CompletedNCT02512302GOLDEN7Updated Oct 25, 2018Results posted

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

A Phase 1 interventional study of SUN-101 via eFlow nebulizer and SUN-101 via eFlow nebulizer with activated charcoal in COPD, sponsored by Sunovion Respiratory Development Inc.. Completed at 2 sites in United Kingdom. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-25.

Sponsored by Sunovion Respiratory Development Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
64th of 73
30 · median 152
Started
2015
with 7 others
Phase 1
7 of 73
none open now
Registered
50th of 73
by date

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 64th largest by enrollment, is one of 8 that started in 2015, is one of 7 in phase 1, and was the 50th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).

Read the detailed description

This is a randomized, open-label, single-dose per dosing period, five-way crossover study in subjects 40 to 70 years of age with a diagnosis of moderate to severe COPD per Global Initiative for Chronic Obstructive Lung Disease guidelines. After a subject provides consent for study participation, there will be a Screening Period lasting up to 3 weeks to determine study eligibility and to allow for appropriate washout of prohibited medications.

Eligible subjects will be randomized to one of 10 treatment Sequences. There will be a minimum of a 7-day washout period between each treatment visit. At each visit, subjects will receive one dose of study medication according to the sequence assigned.

Subjects with a ≥ 20% decrease in forced expiratory volume in one second (FEV1) based on review of the Visit predose value compared with the Screening value will be evaluated by the investigator for continuation in the study.

Subjects taking theophylline will not be able to participate in the study.

03

Conditions studied

  • COPD

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 40 to 70 years-old, inclusive.
  2. A clinical diagnosis of moderate to severe according to the GOLD 2014 guidelines.
  3. Current smokers or ex-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, or equivalent).
  4. Post-bronchodilator (following inhalation of ipratropium bromide) ≥ 30% and ≤ 80% of predicted normal during the Screening Period.
  5. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio ≤ 0.70 during the Screening Period.
  6. Ability to perform reproducible spirometry according to the American Thoracic Society (ATS) and/or European Respiratory Society (ERS) guidelines (2005).
  7. Subject, if female ≤ 70 years of age and of child bearing potential, must have a negative urine pregnancy test at Visit 1. Females of must be instructed to and agree to avoid pregnancy during the study and must use an acceptable method of : a) an oral contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or injectable contraceptive for at least 1 month prior to entering the study with continued use throughout the study and for thirty days following participation; b) barrier method of contraception, eg, condom and /or diaphragm with spermicide while participating in the study; and/or c) abstinence.
  8. Willing and able to remain at the study site for at least 24 hours for each treatment day.
  9. Willing and able to provide written .
  10. Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions that would, in the opinion of the Investigator, preclude the subject from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the subject, included but not limited to the following:

    • Unstable ischemic heart disease (diagnosis of myocardial infarction or admission for acute coronary syndrome) within 6 months of screening.
    • Unstable cardiac arrhythmia or heart failure (change in treatment plan) within 6 months.
    • Treatment for diabetes mellitus within 6 months of screening.
  2. Current evidence or history of a abnormality of cardiac rhythm and/or conduction findings.
  3. Concomitant clinically significant respiratory disease other than (eg, asthma, tuberculosis, bronchiectasis, or other non-specific pulmonary disease).
  4. History of of any organ system treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin.
  5. Recent history of COPD exacerbation requiring hospitalization or need for increased treatments for COPD within 6 weeks prior to the Screening Period.
  6. Use of daily oxygen therapy > 10 hours per day.
  7. Use of oral, intravenous, or intramuscular within 3 months prior to the Screening Period.
  8. Respiratory tract infection within 6 weeks prior to or during the Screening Period.
  9. Significant blood loss (> 500 mL) or donated blood within 60 days preceding screening or plans to donate blood within 60 days after completing the study.
  10. History of or clinically significant ongoing bladder outflow obstruction or history of catheterization for relief of bladder outflow obstruction within the previous 6 months.
  11. History of narrow-angle glaucoma.
  12. Prolonged (> 450 msec for males and > 470 msec for females) during the Screening Period, or history of long QT syndrome.
  13. Recent documented history (previous 12 months) of substance abuse.
  14. .Positive urine drug screen at Visit 1 provided the subject is unable to produce a valid medical rationale for the test result (eg, prescription medication).
  15. Positive HbsAg, antibody, or 1/2 antibody test at Screening.
  16. History of or intolerance to aerosol medications, β2-agonists, anticholinergics, or sympathomimetic amines.
  17. Significant psychiatric disease that would likely result in the subject not being able to complete the study, in the opinion of the Investigator.
  18. Participation in another drug study where drug was received within 30 days prior to the Screening Period, or current participation in another investigational drug trial in which study treatment is being administered, including a SUN-101 study
  19. Previously received SUN-101 (active treatment; formerly known as EP-101).
  20. Previously received any glycopyrrolate product within 28 days of Screening.
  21. Subject is taking theophylline.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SUN-101 via eFlow nebulizer

    50 mcg glycopyrrolate via Electronic Nebulizer

    Drug: SUN-101 via eFlow nebulizer

  • Experimental
    SUN-101 via eFlow nebulizer with activated charcoal

    50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

    Drug: SUN-101 via eFlow nebulizer with activated charcoal

  • Active comparator
    Seebri® Breezhaler®

    63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

    Drug: Seebri® Breezhaler®

  • Active comparator
    Seebri® Breezhaler® with activated charcoal

    : : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

    Drug: Seebri® Breezhaler® with activated charcoal

  • Active comparator
    : Glycopyrrolate Injection

    50 mcg glycopyrrolate via IV infusion

    Drug: Glycopyrrolate Injection

Interventions

  • 50 mcg glycopyrrolate via Electronic Nebulizer

    Also known as: Glycopyrrolate

  • DrugSUN-101 via eFlow nebulizer with activated charcoal

    Drug page: Glycopyrrolate

    50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal

    Also known as: Glycopyrrolate

  • DrugSeebri® Breezhaler®

    63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI

    Also known as: glycopyrronium, glycopyrronium bromide

  • DrugSeebri® Breezhaler® with activated charcoal

    63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal

    Also known as: glycopyrronium, glycopyrronium bromide

  • 50 mcg glycopyrrolate via IV

    Also known as: Glycopyrrolate

06

What researchers measure

Primary outcomes

  1. Cmax

    maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

  2. Area Under the Curve From Time Zero to 24 Hours (AUC0_24)

    Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr

    Time frame: Up to Week 5

  3. Area Under the Curve From Time Zero to Infinity (AUC0_infinity)

    calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / \| λz \| Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

Secondary outcomes

  1. Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate

    calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

  2. Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate

    calculated as Dose/(AUC0-inf\*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

  3. Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate

    The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

  4. Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate

    calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

  5. Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -

    Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: Up to Week 5

  6. Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101

    calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: up to week 5

  7. Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101

    calculated as Dose/(AUC0-∞\* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr

    Time frame: up to week 5

  8. Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101

    The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: up to week 5

  9. Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101

    calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

    Time frame: up to week 5

  10. Dose Normalized Cmax for Seebri and SUN-101.

    Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

    Time frame: up to week 5

  11. Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101

    Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

    Time frame: up to week 5

  12. Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101

    Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

    Time frame: up to week 5

  13. Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101

    Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor\* (AUC0-∞ = AUC0-last+ Clast / \| λz \| ) Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

    Time frame: up to week 5

  14. The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

    An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.

    Time frame: Up to Week 5

  15. The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

    An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.

    Time frame: Up to Week 5

07

Results

Posted Sep 14, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestoneTreatment Group OneTreatment Group TwoTreatment Group ThreeTreatment Group FourTreatment Group FiveTreatment Group SixTreatment Group SevenTreatment Group EightTreatment Group NineTreatment Group Ten
Started3343332333
Completed3243332333
Not completed0100000000
Withdrew: Adverse event0100000000
Period 2
Participant flow — Period 2
MilestoneTreatment Group OneTreatment Group TwoTreatment Group ThreeTreatment Group FourTreatment Group FiveTreatment Group SixTreatment Group SevenTreatment Group EightTreatment Group NineTreatment Group Ten
Started3243332333
Completed3243332332
Not completed0000000001
Withdrew: Adverse event0000000001
Period 3
Participant flow — Period 3
MilestoneTreatment Group OneTreatment Group TwoTreatment Group ThreeTreatment Group FourTreatment Group FiveTreatment Group SixTreatment Group SevenTreatment Group EightTreatment Group NineTreatment Group Ten
Started3243332332
Completed3233332332
Not completed0010000000
Withdrew: Lost to follow-up0010000000
Period 4
Participant flow — Period 4
MilestoneTreatment Group OneTreatment Group TwoTreatment Group ThreeTreatment Group FourTreatment Group FiveTreatment Group SixTreatment Group SevenTreatment Group EightTreatment Group NineTreatment Group Ten
Started3233332332
Completed3233331332
Not completed0000001000
Withdrew: Adverse event0000001000
Period 5
Participant flow — Period 5
MilestoneTreatment Group OneTreatment Group TwoTreatment Group ThreeTreatment Group FourTreatment Group FiveTreatment Group SixTreatment Group SevenTreatment Group EightTreatment Group NineTreatment Group Ten
Started3233331332
Completed3233331332
Not completed0000000000

Outcome measures

PrimaryCmax

maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Geometric mean · Pg/mL
Cmax
Pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal: Glycopyrrolate Injection
Cmax53.75 ± 51.74649.27 ± 60.996166.79 ± 76.348148.03 ± 39.8413787.47 ± 115.166
PrimaryArea Under the Curve From Time Zero to 24 Hours (AUC0_24)

Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr

Time frame:
Up to Week 5
Reported as:
Geometric mean · hr*pg/mL
Area Under the Curve From Time Zero to 24 Hours (AUC0_24)
hr*pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal: Glycopyrrolate Injection
Area Under the Curve From Time Zero to 24 Hours (AUC0_24)172.23 ± 100.974159.12 ± 92.720472.35 ± 90.233428.52 ± 46.9851961.79 ± 142.488
PrimaryArea Under the Curve From Time Zero to Infinity (AUC0_infinity)

calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / \| λz \| Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Geometric mean · hr*pg/mL
Area Under the Curve From Time Zero to Infinity (AUC0_infinity)
hr*pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal: Glycopyrrolate Injection
Area Under the Curve From Time Zero to Infinity (AUC0_infinity)234.23 ± 77.206167.84 ± 41.208607.53 ± 79.340570.90 ± 63.9132550.85 ± 117.068
SecondaryClearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate

calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Geometric mean · Liters/hr
Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate
Liters/hr: Glycopyrrolate Injection
Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate19.60 ± 117.068
SecondaryVolume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate

calculated as Dose/(AUC0-inf\*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Geometric mean · Liters
Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate
Liters: Glycopyrrolate Injection
Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate113.06 ± 131.141
SecondaryTime of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate

The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Median · hr
Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate
hr: Glycopyrrolate Injection
Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate0.100 (0.08 to 0.40)
SecondaryTerminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate

calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Geometric mean · hr
Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate
hr: Glycopyrrolate Injection
Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate3.998 ± 111.8589
SecondaryArea Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -

Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
Up to Week 5
Reported as:
Geometric mean · hr*pg/mL
Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -
hr*pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -182.59 ± 112.339179.78 ± 108.906524.18 ± 99.365485.99 ± 56.588
SecondaryApparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101

calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
up to week 5
Reported as:
Geometric mean · L/hr
Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101
L/hrSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101213.47 ± 77.206297.91 ± 41.208103.70 ± 79.340110.35 ± 63.913
SecondaryApparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101

calculated as Dose/(AUC0-∞\* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr

Time frame:
up to week 5
Reported as:
Geometric mean · liters
Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101
litersSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-1011263.63 ± 31.7161668.59 ± 17.9941305.30 ± 23.5851708.81 ± 22.543
SecondaryTime of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101

The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
up to week 5
Reported as:
Median · hr
Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101
hrSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-1010.317 (0.08 to 12.05)0.250 (0.07 to 12.3)0.250 (0.03 to 1.57)0.250 (0.05 to 0.40)
SecondaryTerminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101

calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.

Time frame:
up to week 5
Reported as:
Geometric mean · hr
Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101
hrSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-1016.554 ± 135.62865.191 ± 61.497110.378 ± 80.189114.866 ± 69.3836
SecondaryDose Normalized Cmax for Seebri and SUN-101.

Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

Time frame:
up to week 5
Reported as:
Geometric mean · Pg/mL
Dose Normalized Cmax for Seebri and SUN-101.
Pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Dose Normalized Cmax for Seebri and SUN-101.85.46 ± 51.74678.33 ± 60.996150.11 ± 76.348133.22 ± 39.841
SecondaryDose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101

Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

Time frame:
up to week 5
Reported as:
Geometric mean · hr*pg/mL
Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101
hr*pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101273.85 ± 100.974253.00 ± 92.720425.12 ± 90.233385.67 ± 46.985
SecondaryDose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101

Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

Time frame:
up to week 5
Reported as:
Geometric mean · hr*pg/mL
Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101
hr*pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101290.32 ± 112.339285.85 ± 108.906471.76 ± 99.365437.39 ± 56.588
SecondaryDose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101

Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor\* (AUC0-∞ = AUC0-last+ Clast / \| λz \| ) Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.

Time frame:
up to week 5
Reported as:
Geometric mean · hr*pg/mL
Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101
hr*pg/mLSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal
Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101372.42 ± 77.206266.86 ± 41.208546.78 ± 79.340513.81 ± 63.931
SecondaryThe Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.

Time frame:
Up to Week 5
Reported as:
Number · participants
The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
participantsSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal: Glycopyrrolate Injection
Adverse Events697117
Serious Adverse Events00000
Adverse events leading to discontinuation11010
SecondaryThe Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation

An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.

Time frame:
Up to Week 5
Reported as:
Number · percentage of participants
The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
percentage of participantsSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal: Glycopyrrolate Injection
Adverse Events20.731.025.040.725.9
Serious Adverse Events00000
Adverse events leading to discontinuation3.43.403.70

Adverse events

Collected over up to week 5. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SUN-101 Via eFlow Nebulizer—0/29 (0%)1/29 (3.4%)
SUN-101 Via eFlow Nebulizer With Activated Charcoal—0/29 (0%)3/29 (10.3%)
Seebri® Breezhaler®—0/28 (0%)3/28 (10.7%)
Seebri® Breezhaler® With Activated Charcoal—0/27 (0%)5/27 (18.5%)
: Glycopyrrolate Injection—0/27 (0%)4/27 (14.8%)
Most frequent other events
Most frequent other events
EventSUN-101 Via eFlow NebulizerSUN-101 Via eFlow Nebulizer With Activated CharcoalSeebri® Breezhaler®Seebri® Breezhaler® With Activated Charcoal: Glycopyrrolate Injection
headacheNervous system disorders1/293/291/284/274/27
back painMusculoskeletal and connective tissue disorders0/290/292/281/270/27

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Total
<=18 years0
Between 18 and 65 years22
>=65 years8
Sex: Female, Male
Sex: Female, Male(Participants)Total
Female6
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total
Hispanic or Latino0
Not Hispanic or Latino30
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White28
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Total
United Kingdom30
08

Study locations

2 sites
  • Queen Anne Street Medical Center
    London, W1G 8HU, United Kingdom
  • Medicines evaluation Unit Ltd.
    Manchester, M23 9QZ, United Kingdom
09

References and documents

Publications

  • Leaker BR, Singh D, Nicholson GC, Hezelova B, Goodin T, Ozol-Godfrey A, Galluppi G, Barnes PJ. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. Respir Res. 2019 Jun 28;20(1):132. doi: 10.1186/s12931-019-1113-z. PubMed 31253162 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2015
First posted
Jul 30, 2015
Start
Oct 2015
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Sep 14, 2018
Last update
Oct 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02512302
Responsible party
Sponsor
First posted
Jul 30, 2015
Start date
Oct 2015
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Sep 14, 2018
Last update
Oct 25, 2018

Study contacts

Head of Global Clinical, Respiratory and Bio-threapeutics
study chair · Sunovion Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion